AANS Beyond 2021: Trauma Bundle-New Innovations in VTE Chemoprophylaxis

Video Transcription

Video Summary

The video discusses the latest research on venous thromboembolism (VTE) chemoprophylaxis in neurosurgical patients. The speaker, Brad Dengler, is a neurosurgeon and neurointensivist at Walter Reed National Military Medical Center. He covers various studies evaluating different methods of chemoprophylaxis and their outcomes in the neurosurgical patient population.<br /><br />Some key points from the video include:<br /><br />- Low molecular weight heparin has shown to decrease mortality and the overall rate of VTE events in medical and trauma intensive care units.<br />- Studies have compared unfractionated heparin and low molecular weight heparin, and there is ongoing debate about which is better.<br />- One study found that the low molecular weight heparin group had more parenchymal hematomas, contusions, and intraventricular hemorrhages, but also had fewer venous thromboembolic events compared to the unfractionated heparin group.<br />- Another study found that early initiation of VTE chemoprophylaxis was associated with a lower risk of VTE events.<br />- Patients with traumatic brain injury treated with low molecular weight heparin had a lower odds ratio of mortality and VTE events.<br />- It is important to consider factors such as patient weight, risk factors for VTE, and accurate dosing when determining the best chemoprophylaxis strategy.<br /><br />No credits were mentioned in the video transcript.

Keywords

VTE

chemoprophylaxis

neurosurgical patients

low molecular weight heparin

unfractionated heparin

mortality

traumatic brain injury